Authors: Andrew Ciupek, PhD, Associate Director of Clinical Research; Heather Law, MA, Associate Director of Lung Cancer Registry; Shanada Monestime, PharmD, BCOP, Director of Community Engaged Research; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program 2022 was an exciting [...]
Authors: Renee Botello, MSc, Treatment and Trial Navigator; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program In 2022, the treatment landscape for lung cancer continued to evolve to provide breakthrough treatment options for people living with lung cancer. This [...]
Lung cancer mortality has been declining steadily in the past two decades and the good news is the pace of the improvements have picked up! Last week, the American Cancer Society released their 2022 stats and share that the [...]
On January 26, 2023, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for adjuvant (additional) treatment following surgery and chemotherapy for stage IB, II, or IIIA non-small cell lung cancer (NSCLC). This approval was based on the [...]
Question: My tumor’s original biopsy showed that I had non-small cell lung cancer with an EGFR biomarker. Recently, the cancer started progressing and my most recent biopsy shows that I have transformed small cell lung cancer. What does this [...]
On December 12th, 2022, the Food and Drug Administration (FDA) approved Krazati (adagrasib) for treatment of non-small cell lung cancer (nsclc) where there is a KRAS G12C mutation. This approval is for patients who have received at least one line [...]
A popular way to talk about the incredible progress that has been made in lung cancer treatments over the past few years is to share the statistic that more lung cancer treatments have been approved in the past three [...]
SAN CARLOS, Calif., (November 30, 2022) – The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, has launched the SPARK Study to help researchers better understand treatment resistance in patients with KRAS-positive lung cancer and [...]
On November 10th, 2022, the Food and Drug Administration (FDA) approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for treatment of non-small cell lung cancer where there are no changes in ALK or EGFR. The FDA [...]
On November 8th, 2022, the Food and Drug Administration (FDA) approved Libtayo (cemiplimab-rwlc) for treatment of non-small cell lung cancer where there are no changes in ALK, EGFR or ROS1 in combination with platinum doublet chemotherapy. The FDA based [...]